Ovid Therapeutics Announces Participation in Two Upcoming Investor Conferences

NEW YORK–(BUSINESS WIRE)– Ovid Therapeutics, Inc., a privately held biopharmaceutical company
focused on developing therapies for orphan diseases of the brain, today
announced its participation in two upcoming investor conferences:

• Citi 11^th Annual Biotech Conference. Members of the
  company’s management team will participate in one-on-one meetings on
  Wednesday, September 7, 2016, at the Mandarin Oriental Hotel in Boston.
• Baird Global Healthcare Conference. Yaron Werber, M.D., chief business
  and financial officer of Ovid, will present on Thursday, September 8,
  2016, at 9:40 a.m. ET at the New York Palace in New York City.

About Ovid Therapeutics, Inc.

Ovid Therapeutics, Inc. is a privately held, New York-based,
biopharmaceutical company committed to transforming the lives of
patients with orphan diseases of the brain. Ovid focuses on patients and
their unmet medical needs. Using the significant operational, product
development and business development experience of its management team,
Ovid aims to become a leading neurology company, with multiple products
and a rich pipeline, coupled with compelling research and development.
Ovid has raised $80M in substantially oversubscribed financings led by
Fidelity Management and Research Company and including Cowen Private
Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management,
Sphera Global Healthcare Fund, Jennison Associates, Redmile Group,
DoubleLine Equity Healthcare Fund, and Cormorant Asset Management, as
well as additional blue chip mutual funds and leading life sciences
investors.

For more information on Ovid, please visit http://www.ovidrx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160901005635/en/